CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells

Autor: Benoit-Lizon, Isis, Jacquin, Elise, Rivera Vargas, Thaiz, Richard, Corentin, Roussey, Aurélie, Dal Zuffo, Ludivine, Martin, Tiffany, Melis, Andréa, Vinokurova, Daria, Shahoei, Sayyed Hamed, Baeza Garcia, Alvaro, Pignol, Cassandre, Giorgiutti, Stéphane, Carapito, Raphaël, Boidot, Romain, Végran, Frédérique, Flavell, Richard A, Ryffel, Bernhard, Nelson, Eric R, Soulas-Sprauel, Pauline, Lawrence, Toby, Apetoh, Lionel

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer, 2022, 10, ⟨10.1136/jitc-2021-003459⟩

International audience; Background While stimulator of interferon genes (STING) activation in innate immune cells of the tumor microenvironment can result in CD8 T cell-dependent antitumor immunity, whether STING signaling affects CD4 T-cell response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::01863b8c4aab777d62f2af4b1f49d57f
http://europepmc.org/articles/PMC8804688

Evaluating the Economic Impact of a Special Credit Programme: KIK?KMKP in Indonesia.

Autor: Bolnick, Bruce R., Nelson, Eric R.

Publikováno v: Journal of Development Studies. Jan90, Vol. 26 Issue 2, p299. 14p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T H 1 and T H 9 cells.

Autor: Benoit-Lizon I; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Jacquin E; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.; INSERM, UMR-S 1193, Université Paris-Saclay, Châtenay-Malabry, France., Rivera Vargas T; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Richard C; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Roussey A; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Dal Zuffo L; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Martin T; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Melis A; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Vinokurova D; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Shahoei SH; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.; Department of Molecular and Integrative Physiology, University of Illinois at Urbana Champaign, Urbana, IL, USA., Baeza Garcia A; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Pignol C; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France., Giorgiutti S; INSERM UMR - S1109, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France., Carapito R; Laboratoire d'ImmunoRhumatologie Moléculaire, GENOMAX platform, INSERM UMR_S 1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), LabEx TRANSPLANTEX, Strasbourg, France., Boidot R; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.; Department of Biology and Pathology of Tumors, Centre Georges François Leclerc, Dijon, France., Végran F; INSERM, U1231, Dijon, France.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.; Department of Biology and Pathology of Tumors, Centre Georges François Leclerc, Dijon, France., Flavell RA; Department of Immunobiology, Yale University School of Medicine, New Heaven, CT, USA., Ryffel B; UMR 7355, Experimental and Molecular Immunology and Neurogenetics, CNRS, Orléans, France.; Department of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Nelson ER; Department of Molecular and Integrative Physiology, University of Illinois at Urbana Champaign, Urbana, IL, USA.; Anticancer Discovery from Pets to People Theme, University of Illinois Urbana-Champaign, Cancer Center at Illinois, Urbana Champaign, Illinois, USA.; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, IL, USA., Soulas-Sprauel P; INSERM UMR-S1109, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Faculty of Pharmacy, Université de Strasbourg, Strasbourg, France., Lawrence T; Centre d'Immunologie de Marseille-Luminy, Université Aix-Marseille, INSERM, CNRS, Marseille, France., Apetoh L; INSERM, U1231, Dijon, France lionel.apetoh@inserm.fr.; UFR Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.; INSERM, U1100, Tours, France.; Faculté de Médecine, Université de Tours, Tours, France.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1).